Buprenorphine Therapy for Opioid Addiction

Medication Selection and Formulation

• The American Academy of Family Physicians recommends buprenorphine/naloxone (Suboxone) as the preferred formulation for most patients with opioid use disorder due to its safety features that prevent misuse by crushing and injecting 1
• The therapeutic dose range for most patients is 8-16 mg daily, with a target of 16 mg for most patients 2, 3

Treatment Initiation Protocol

• Buprenorphine should only be administered to patients in active opioid withdrawal to prevent precipitated withdrawal 2, 3
• Confirm time since last opioid use before initiating treatment, with guidelines including: short-acting opioids (e.g., heroin): >12 hours, extended-release formulations: >24 hours, and methadone maintenance: >72 hours 2, 3
• Assess withdrawal severity using a validated tool such as the Clinical Opiate Withdrawal Scale (COWS) 2, 3

Maintenance Treatment Plan

• Prescribe buprenorphine/naloxone at a target dose of 16 mg daily for most patients 2, 3
• Treatment should be combined with counseling and behavioral therapies to provide a "whole-patient" approach 2, 3, 4

Monitoring and Follow-up

• Regular monitoring through urine drug testing to assess for continued illicit opioid use 4
• Assess for the presence of opioid use disorder using DSM-5 criteria during follow-up visits 4
• Consider hepatitis C and HIV screening as part of comprehensive care 2, 3

Special Considerations

• For patients requiring acute pain management while on buprenorphine maintenance, continue the usual dose of buprenorphine and use short-acting opioid analgesics as needed for breakthrough pain 5, 6
• For perioperative management, decision to continue or hold buprenorphine should be individualized based on the prescribed daily dose, indication for treatment, risk of relapse, and expected level of post-surgical pain 7

Common Pitfalls and Challenges

• Buprenorphine should never be initiated while patients are still under the influence of full opioid agonists to avoid precipitated withdrawal 2, 3
• Concomitant use of buprenorphine with QT-prolonging agents is contraindicated due to risk of cardiac complications 7

Treatment Failure Management

• For patients with complex needs, consider referral to specialized addiction treatment programs 4

Opioid Addiction Treatment with Buprenorphine Formulations

Medication Characteristics

• Subutex contains only buprenorphine, a partial opioid agonist, whereas Suboxone contains buprenorphine plus naloxone in a 4:1 ratio 8, 9
• Buprenorphine (in both medications) is a partial mu-opioid receptor agonist with high receptor affinity, providing gentle stimulation of the opioid system, ameliorating withdrawal symptoms, and reducing cravings 9, 10

Clinical Indications and Administration

• Subutex may be preferred in specific situations such as pregnancy, documented naloxone allergy, or patients with severe chronic pain who may need divided doses 10
• For patients with chronic pain, buprenorphine can be administered in divided doses (every 6-8 hours) for better pain control 10
• Both medications significantly reduce illicit opioid use compared to placebo, according to the American College of Physicians, as reported in the Annals of Internal Medicine 11

Special Considerations

• Patients on buprenorphine maintenance may require dosage adjustments or additional analgesics for pain management, as recommended by the Clinical Infectious Diseases society 10
• Buprenorphine's high binding affinity may block effects of other opioids at lower doses, as noted by the Clinical Infectious Diseases society 10

Guideline Recommendations for Buprenorphine/Naloxone Maintenance in Opioid Use Disorder

Assessment of Co‑Occurring Substance Use

• Clinicians should routinely screen patients on buprenorphine/naloxone for concurrent use of alcohol, benzodiazepines, cocaine, methamphetamine, and other non‑prescribed substances. Evidence level: not specified. 12

Social and Functional Evaluation

• Evaluation of employment and educational status is recommended as part of comprehensive care for individuals receiving buprenorphine/naloxone. Evidence level: not specified. 12
• Assessment of the patient’s support system and family involvement should be incorporated into treatment planning for buprenorphine/naloxone maintenance. Evidence level: not specified. 13

Laboratory Monitoring

• Routine liver function testing every 3–6 months is not required for patients maintained on buprenorphine/naloxone, distinguishing it from naltrexone monitoring requirements. Evidence level: not specified. 12

Mental Health Screening

• Systematic screening for depression, anxiety, post‑traumatic stress disorder, and other common psychiatric comorbidities is advised for patients on buprenorphine/naloxone. Evidence level: not specified. 13
• Evaluation of sleep quality and identification of insomnia should be included in routine assessments of this population. Evidence level: not specified. 13

Safety and Risk Management

• Abrupt discontinuation of buprenorphine/naloxone markedly increases the risk of opioid overdose and death because of reduced opioid tolerance. Evidence level: not specified. 12

Pain Management Considerations

• When acute pain arises in a patient maintained on buprenorphine/naloxone, the maintenance dose should be continued and short‑acting opioid analgesics added for breakthrough pain; higher opioid doses may be necessary due to buprenorphine’s high receptor affinity. Evidence level: not specified. 13
• Buprenorphine may be employed off‑label for chronic pain in patients who experience inadequate pain control or persistent dependence symptoms while on maintenance therapy. Evidence level: not specified. 13

Clinical Monitoring and Acute Pain Management for Patients on Buprenorphine/Naloxone Maintenance

Routine Vital Sign Documentation

• In stable patients receiving buprenorphine/naloxone maintenance, clinicians should record blood pressure, heart rate, respiratory rate, and temperature at each follow‑up visit to monitor overall health status. 14

Assessment of Injection‑Related Physical Findings

• During physical examinations of patients on buprenorphine/naloxone, providers should look for signs of injection drug use (e.g., track marks, skin abscesses) to identify ongoing high‑risk behaviors. 14

Acute Pain Management Strategies

• When a patient on buprenorphine/naloxone experiences acute pain, the current recommendation is to maintain the existing buprenorphine dose and supplement with short‑acting opioid analgesics for breakthrough pain; higher opioid doses may be necessary because buprenorphine’s high receptor affinity can limit analgesic effectiveness. 14

Management of Opioid Use Disorder: Psychosocial Stability and Support

Constitutional Assessment

• Patients with opioid use disorder in maintenance therapy commonly report absence of fever, chills, and night sweats, indicating no acute systemic infection or withdrawal‑related autonomic symptoms 15.

Psychosocial Environment

• A stable psychosocial environment—characterized by supportive relationships, secure housing, and steady employment—is associated with sustained remission in individuals receiving medication‑assisted treatment for opioid use disorder 15.

Engagement in Mutual‑Help Resources

• Ongoing participation in mutual‑help groups such as Alcoholics Anonymous, Narcotics Anonymous, or SMART Recovery is recommended to reinforce recovery and reduce relapse risk for patients on buprenorphine/naloxone maintenance therapy 15.

Management of Acute Pain, Monitoring, and Support for Patients on Buprenorphine/Naloxone Maintenance

Acute Pain Management

Monitoring and Safety

Psychosocial Support

Overdose Risk and Medication Safety in Patients on Opioid Maintenance Therapy with Concurrent Alcohol Use

Risk of Overdose

• Patients receiving opioid maintenance therapy who also consume alcohol have a markedly increased risk of respiratory depression and fatal overdose if they relapse to opioid use, because alcohol potentiates opioid‑induced respiratory suppression. 20

Medication Interaction Safety

• Combining alcohol with sedating medications (e.g., benzodiazepines, hypnotics, or other central nervous system depressants) substantially heightens the danger of respiratory depression and overdose in individuals on opioid maintenance therapy. 20